Callan JMB Inc. (CJMB) shareholders
Close on Nov 17, 2026Market cap $2.07MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bard Associates Inc | 245,682 | 5.30% | 13G (passive) amendment | Dec 4, 2025 |
| Ionic Ventures, LLC Joint filing with Ionic Management, LLC (5.50%), Brendan O'Neil (5.50%) and 1 more | 233,725 | 5.50% | 13G (passive) | Feb 5, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CJMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Creative Planning | 255,693 | 4.45% | $205.58K | – | 0.00% |
| Bard Associates Inc | 229,250 | 3.99% | $184.32K | −16,232 | 0.04% |
| Citadel Advisors LLC | 32,086 | 0.56% | $25.80K | New | 0.00% |
| Axxcess Wealth Management, LLC | 25,000 | 0.43% | $20.10K | New | 0.00% |
| Geode Capital Management, LLC | 15,672 | 0.27% | $12.60K | −7,297 | 0.00% |
| Financial Plan, Inc. | 13,500 | 0.23% | $10.85K | New | 0.01% |
| Citigroup Inc | 13,423 | 0.23% | $10.79K | New | 0.00% |
| HighTower Advisors, LLC | 12,500 | 0.22% | $10.05K | – | 0.00% |
| XTX Topco Ltd | 11,287 | 0.20% | $9.08K | New | 0.00% |
| Vanguard Capital Management LLC | 6,664 | 0.12% | $5.36K | – | 0.00% |
| UBS Group AG | 5,643 | 0.10% | $4.54K | +4,009 | 0.00% |
| Qsemble Capital Management, LP | 1,561 | 0.03% | $377.67K | −3,267 | 0.05% |
| Tower Research Capital LLC (TRC) | 434 | 0.01% | $349 | −1,636 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | 0.00% | $1 | −1 | 0.00% |
| Barclays PLC | 1 | 0.00% | $1 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 1M | 10.8% | 6 / 1 | 5 / 3 | 0M | 0M |
| Q1 2026 | 12 | 1M | 10.4% | 7 / 2 | 2 / 7 | 0M | 0M |
| Q4 2025 | 12 | 1M | 12.7% | 5 / 3 | 1 / 2 | 0M | 0M |
| Q3 2025 | 9 | 1M | 13.0% | 0 / 1 | 5 / 0 | 0M | 0M |
| Q2 2025 | 9 | 1M | 12.2% | 2 / 3 | 2 / 0 | 0M | 0M |
| Q1 2025 | 7 | 1M | 12.0% | 7 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
3 funds held CJMB in Q2 2026, 25% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CJMB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 18,248 | 0.32% | $13.32K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 6,664 | 0.12% | $5.36K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 2,066 | 0.04% | $1.51K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Wayne D. Williams | CEO, Chairman and President, Director, 10% owner | 2,377,468 | 41.33% | Dec 18, 2025 |
| Eric L. Kash | Executive Vice President, Director | – | – | Feb 12, 2025 |
| David J. Croyle | Chief Medical Officer, 10% owner | 1,550,000 | 26.95% | Mar 26, 2026 |
| Jeffrey Appleman | Chief Financial Officer | – | – | Feb 12, 2025 |
| Gerald Dial | Director | 12,000 | 0.21% | Jun 1, 2026 |
| Liberty Smith Duke | Director | 1,512 | 0.03% | Dec 10, 2025 |
| Mark Meller | Director | – | – | Feb 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David J. Croyle Chief Medical Officer, 10% owner | Mar 20, 2026 | Buy | +10,195 | $1.75 | $17.84K | 800,000 |
| David J. Croyle Chief Medical Officer, 10% owner | Mar 6, 2026 | Buy | +14,805 | $1.76 | $26.06K | 789,805 |
| Gerald Dial Director | Dec 30, 2025 | Buy | +10,000 | $0.76 | $7.60K | 12,000 |
| Gerald Dial Director | Dec 30, 2025 | Buy | +461 | $1.22 | $562 | 461 |
| Gerald Dial Director | Dec 30, 2025 | Buy | +1,539 | $1.20 | $1.85K | 2,000 |
| Wayne D. Williams CEO, Chairman and President, Director, 10% owner | Dec 16, 2025 | Buy | +5,000 | $1.73 | $8.65K | 84,355 |
| Wayne D. Williams CEO, Chairman and President, Director, 10% owner | Dec 15, 2025 | Buy | +10,810 | $1.70 | $18.38K | 79,355 |
| Wayne D. Williams CEO, Chairman and President, Director, 10% owner | Dec 12, 2025 | Buy | +4,926 | $1.75 | $8.62K | 2,267,488 |
| Wayne D. Williams CEO, Chairman and President, Director, 10% owner | Dec 11, 2025 | Buy | +62 | $1.79 | $111 | 2,262,562 |
| Wayne D. Williams CEO, Chairman and President, Director, 10% owner | Dec 11, 2025 | Buy | +30,856 | $1.65 | $50.91K | 68,545 |
| Wayne D. Williams CEO, Chairman and President, Director, 10% owner | Dec 10, 2025 | Buy | +13,689 | $1.65 | $22.59K | 38,689 |
| Liberty Smith Duke Director | Dec 9, 2025 | Buy | +612 | $1.52 | $930 | 1,512 |
| Liberty Smith Duke Director | Dec 8, 2025 | Buy | +900 | $1.56 | $1.40K | 900 |
| David J. Croyle Chief Medical Officer, 10% owner | Mar 27, 2025 | Buy | +25,000 | $4.50 | $112.50K | 775,000 |
| David J. Croyle Chief Medical Officer, 10% owner | Feb 5, 2025 | Buy | +24,375 | $4.00 | $97.50K | 24,375 |
| Wayne D. Williams CEO and President, Director, 10% owner | Feb 5, 2025 | Buy | +12,500 | $4.00 | $50.00K | 2,262,500 |
| Wayne D. Williams CEO and President, Director, 10% owner | Feb 5, 2025 | Buy | +25,625 | $4.00 | $102.50K | 25,625 |
| Wayne D. Williams CEO and President, Director, 10% owner | Feb 5, 2025 | Buy | +25,000 | $4.00 | $100.00K | 25,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Callan JMB's stock actually held short. Settlement fails (shares not delivered on time) peaked at 189,834 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?